wiseowl research - 7.6c buy recommendation, page-106

From chairmans address at last AGM on Nov 24:

I will now go on to summarize what we have learnt from our high level detailed discussions with the US multinational medical device companies. In short they see women’s pelvic floor issues as massive global market especially in first and second world countries. They have indicated that they want to be in this market. Currently there is no major multinational in this space. They see the PeriCoach as the only FDA, CE and TGA registered medical device in this field with strong clinical evidence from both Australia and North America supporting our medical claims for the PeriCoach. They see the PeriCoach as an alternative to pelvic floor surgery and in the most severe cases as an adjunct to surgery. The version of the PeriCoach that they want is the V3 as the market potential for the V3 is far greater. Over the coming months we intend to release the V3 and to quickly gather as much clinical evidence as possible. This evidence on the V3 will supplement the mass of clinical evidence and data that we already have on the V2 PeriCoach. At this stage, we intend to reengage with the New York based Investment Banks with view to holding an auction. This auction will not only be for PeriCoach but also for the AutoStart Burette.